



## IPO Note- Mankind Pharma Limited

24 April 2023

Mankind Pharma Ltd. (MPL) incorporated in 1991 is a well-known and fastest growing player in Indian pharma market and the 4<sup>th</sup> largest in terms of domestic sales and 3<sup>rd</sup> largest in terms of domestic sales volume as on Dec'22 MAT (Moving Annual Total). MPL develops and manufactures pharma formulations across various acute and chronic therapeutic areas and owns several consumer healthcare brands. MPL has around 36 brands including Manforce, Prega News, Unwanted -72, Moxikind and Nurokind, with several products ranking in Top 10 in the covered markets.

### Strong domestic market position through a diversified product portfolio:-

MPL focuses primarily on the domestic market (98% of sales) with market share increasing from 4.1% to 4.3% over FY20 - MAT Dec'22 with sales growing at 12% CAGR v/s IPM (Indian Pharmaceutical Market) growth of around 10% for the same period. MPL entered in consumer healthcare business in 2007 and has established dominant presence in the condoms, pregnancy detection, contraceptives, antacid, vitamin & mineral supplements and antiacne categories with their brands Manforce/ Prega News/ Unwanted- 72 having a market share of 30%/ 80%/ 62% respectively. MPL is also present in several acute and chronic therapeutic areas in India with their covered market presence in the IPM increasing to 69% in MAT Dec'22 and focusing on increasing penetration in the chronic segment which is expected to grow at a CAGR of 11% - 13% over the next 5 years and launched new divisions in anti-diabetic, cardiovascular, neuro/CNS and respiratory areas.

### Pan- India market presence with strong brand recall:-

MPL has a pan-India marketing presence (field force of 11,691 medical representatives and 3,561 field managers) and one of the largest distribution networks in the IPM with over 80% of doctors in India prescribing its formulations for MAT Dec'22. This has aided MPL to garner a strong brand recognition with several of its products gaining leadership positions in its covered markets. Their Domestic Sales from metro and Class I cities contributed around 53% while the rest comes from other than metro cities.

**Key Risks:-** 1) Any price control reforms from Government may affect margins. 2) High competition in generic segment. 3) Highly regulated industry.

### Decent financials & valuation – SUBSCRIBE

At the upper price band, MPL is available at PE of ~33x its expected FY23 EPS. As at FY22, the D/E stands at 0.09x while its Net Working Capital Cycle was at 49 days. We believe that MPL's market leadership and brand recognition coupled with Management's bet on the recent acquisition of Panacea Biotech's formulations may provide a huge growth opportunity for the company. We have a **SUBSCRIBE** recommendation to this issue.

Key Financials (₹ Cr)	Mar-20	Mar-21	Mar-22	9MFY23
Revenue	5,865.2	6,214.4	7,781.6	6,696.8
EBITDA	1,448.4	1,659.8	2,003.8	1,493.6
EBITDA Margin (%)	24.7%	26.7%	25.8%	22.3%
PAT	1,056.2	1,293.0	1,453.0	1,016.0
PAT Margin (%)	18.0%	20.8%	18.7%	15.2%
Net Worth	3,485.3	4,722.0	6,155.2	7,145.9
ROCE (%) (Not annualized for 9MFY23)	35.9%	30.4%	25.5%	16.6%
ROE (%) (Not annualized for 9MFY23)	31.8%	30.3%	26.0%	14.9%
Net Working Capital Days	34	40	49	53

Source: ABML Research, RHP, company presentation

### Aditya Birla Money Ltd.

10th Floor, R - Tech Park, Nirlon Knowledge Park, Off Western Express Highway,  
Goregaon (E), Mumbai - 400 063  
+91 22 6225 7600

care.stocksandsecurities@adityabirlacapital.com | www.stocksandsecurities.adityabirlacapital.com

Rating	SUBSCRIBE	
<b>Issue Details</b>		
Issue Opens	25-Apr-23	
Issue Closes	27Apr-23	
Face Value (₹)	1	
Price Band (₹)	1,026-1,080	
Bid Lot	13	
Issue Size at higher price band (₹ Cr)	4,326	
Market cap @ upper price band (₹ cr)	43,264	
Listing	NSE/BSE	
BRLMs	Axis Capital, Kotak Mahindra Capital, IIFL Securities, Jefferies, JP Morgan	
Registrar	KFin Tech Ltd	
<b>Shareholding Pattern (%)</b>		
	<b>Pre Issue</b>	<b>Post Issue</b>
Promoter	79	76.5
Public	21	23.5
<b>Issue Structure (In cr no. of shares)</b>		
Issue size	4.0	
OFS	4.0	
<b>Break-up of net issue to public (%):</b>		
QIB's portion	50.0	
Non-Institutional portion	15.0	
Retail Portion	35.0	

Source: ABML Research, RHP

### Analyst Details

Mihir B. Manek

022-6819 0520

mihir.manek1@adityabirlacapital.com

Registered Office:

Indian Rayon Compound, Veraval,  
Gujarat - 362 266

CIN: L65993GJ1995PLC064810



## IPO Note- Mankind Pharma Limited

24 April 2023

### Disclaimer:

This document is not for public distribution and is meant solely for the personal information of the authorised recipient. No part of the information must be altered, transmitted, copied, distributed or reproduced in any form to any other person. Persons into whose possession this document may come are required to observe these restrictions. This document is for general information purposes only and does not constitute an investment advice or an offer to sell or solicitation of an offer to buy / sell any security and is not intended for distribution in countries where distribution of such material is subject to any licensing, registration or other legal requirements.

The information, opinion, views contained in this document are as per prevailing conditions and are of the date appearing on this material only and are subject to change. No reliance may be placed for any purpose whatsoever on the information contained in this document or on its completeness. Neither Aditya Birla Money Limited (ABML), its group companies, its directors, associates, employees nor any person connected with it accepts any liability or loss arising from the use of this document. The views and opinions expressed herein by the author in the document are his own and do not reflect the views of Aditya Birla Money Limited or any of its associate or group companies. The information set out herein may be subject to updation, completion, revision, verification and amendment and such information may change materially. Past performance is no guarantee and does not indicate or guide to future performance.

Nothing in this document is intended to constitute legal, tax or investment advice, or an opinion regarding the appropriateness of any investment, or a solicitation of any type. The contents in this document are intended for general information purposes only. This document or information mentioned therefore should not form the basis of and should not be relied upon in connection with making any investment. The investment may not be suited to all the categories of investors. The recipients should therefore obtain their own professional, legal, tax and financial advice and assessment of their risk profile and financial condition before considering any decision.

Aditya Birla Money Limited, its associate and group companies, its directors, associates, employees from time to time may have various interests/ positions in any of the securities of the Company(ies) mentioned therein or be engaged in any other transactions involving such securities or otherwise in other securities of the companies / organization mentioned in the document or may have other interest with respect to any recommendation and / related information and opinions. The company follows Employee Trading Policy which regulates the trading activities of the research analysts. The compensation of the research analysts is governed as per the Board approved "Research Analyst" Policy.

Aditya Birla Money Limited is acting as a Research Analyst and is registered under SEBI (Research Analyst) Regulations, 2014. SEBI Registration No. INH000002145

### Aditya Birla Money Ltd.

10th Floor, R - Tech Park, Nirlon Knowledge Park, Off Western Express Highway,  
Goregaon (E), Mumbai - 400 063  
+91 22 6225 7600

care.stocksandsecurities@adityabirlacapital.com | www.stocksandsecurities.adityabirlacapital.com

### Registered Office:

Indian Rayon Compound, Veraval,  
Gujarat - 362 266

CIN: L65993GJ1995PLC064810